Luxfer Holdings plc — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter results filing. Luxfer is a global industrial materials and gas-cylinder manufacturer with continuing operations in Gas Cylinders, Elektron and Graphic Arts.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $405.0 million | $423.4 million |
| Gross profit; gross margin | $76.6 million; 18.9% | $95.0 million; 22.4% |
| Operating income; operating margin | $4.2 million; 1.0% | $44.8 million; 10.6% |
| Continuing-operations net income (loss) | $(2.6) million | $32.0 million |
| Total net income (loss), including discontinued operations | $(1.9) million | $26.9 million |
| Continuing-operations diluted EPS | $(0.10) | $1.16 |
| Adjusted EBITDA from continuing operations (non-GAAP) | $38.8 million | $63.1 million |
| Cash provided by operating activities, continuing operations | $26.2 million | $15.8 million |
| Capital expenditures | $9.4 million | $8.3 million |
Cash and cash equivalents were $2.3 million at year-end, plus $0.3 million restricted cash. Debt was $72.2 million net of issuance costs on the balance sheet ($25.0 million 2026 notes, $43.1 million drawn on the revolving credit facility and $4.6 million overdraft before issuance costs). The $125 million revolving facility had $81.9 million undrawn. The company reported compliance with debt covenants through year-end. Current assets were $168.8 million and current liabilities $64.8 million.
Material changes and segment results
- Sales fell 4.3% year over year. Volume and mix reduced revenue by $43.1 million, partly offset by $25.0 million of material-cost-related price increases. Gross margin declined 3.5 percentage points, reflecting mix and input costs.
- Gas Cylinders: Sales rose 1.5% to $186.4 million; adjusted EBITDA increased to $16.7 million from $12.8 million. SCBA and medical cylinder growth and contract repricing helped, while industrial and alternative-fuel cylinder sales weakened.
- Elektron: Sales declined 6.9% to $187.1 million; adjusted EBITDA fell to $26.6 million from $42.5 million. Lower SoluMag and commercial magnesium-powder sales and adverse mix weighed on results; zirconium pharmaceutical products and chemical response kits were areas of strength.
- Graphic Arts: Sales fell 18.6% to $31.5 million, and adjusted EBITDA shifted to a $4.5 million loss from $7.8 million income. Lower plate demand, magnesium costs, competition and pricing pressure were cited. The company separated Graphic Arts as a reportable segment in 2023.
- Cash from operations improved as receivables and inventory balances declined from prior-year elevated levels. Financing cash outflow was $27.5 million, including repayment of $25.0 million notes, $14.0 million dividends and $2.7 million share repurchases; borrowing-facility drawdowns partly offset these outflows.
Outlook, risks and unusual items
- No specific full-year 2024 revenue or earnings guidance is provided. Management expects raw-material, energy, labor and transport pressures to ease overall in 2024, while noting substantial uncertainty about the scale and timing. Falling magnesium prices are expected to reduce input costs during 2024, with cost recognition potentially lagging purchases.
- Management expects 2024 capital expenditures of $11 million to $14 million. Priorities include cost control, productivity, product launches, cash generation and working capital discipline, and renegotiating Gas Cylinders contracts; the longest constrained contract was not due for renewal until mid-2024.
- Following a strategic review, Luxfer intends to divest Graphic Arts in 2024. The company also expects to sell its remaining Superform U.S. business within the next 12 months; it is classified as discontinued operations/held for sale.
- Unusual FY2023 charges included a $12.7 million Graphic Arts impairment, $6.4 million restructuring charges, $5.9 million of Elektron legal costs within SG&A, and a $7.6 million defined-benefit pension charge. The pension charge primarily reflected settlement of the U.S. pension plan; the reported income-tax benefit was $7.1 million despite a pretax loss.
- Key exposures include magnesium supply disruption (U.S. Magnesium deliveries had ceased; alternatives were qualified), volatile aluminum and carbon-fiber costs, customer concentration, end-market cyclicality, foreign exchange, floating-rate debt, pension assumptions, product liability, environmental regulation and cybersecurity. Two lawsuits related to a third-party waste-site explosion remain ongoing; the company says potential liability and reasonable defense costs are insured and does not expect a material financial impact.
- Management and the auditor identified a material weakness in internal control over financial reporting involving controls for inventory in transit. No financial-statement misstatement was identified, but remediation was ongoing. The auditor concluded internal control over financial reporting was ineffective at December 31, 2023; the financial-statement audit opinion was unmodified.
Important facts for investors to verify
- Progress, terms and timing of the planned Graphic Arts and Superform U.S. divestitures, and any resulting proceeds or additional charges.
- Whether the inventory-in-transit control weakness is remediated and controls operate effectively in subsequent reporting periods.
- Whether magnesium input-cost relief and Gas Cylinders contract repricing improve margins, and whether expected cost savings require customer price reductions.
- Cash generation, working-capital needs, borrowing levels and headroom under debt covenants as the company funds capital spending and dividends.
- The outcome and insurance recovery associated with the ongoing waste-site litigation, and the results of the U.K. pension plan’s next actuarial valuation.